株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ベッカー型筋ジストロフィー:パイプライン製品の分析

Becker Muscular Dystrophy - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 321917
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.80円で換算しております。
Back to Top
ベッカー型筋ジストロフィー:パイプライン製品の分析 Becker Muscular Dystrophy - Pipeline Review, H2 2017
出版日: 2017年08月22日 ページ情報: 英文 46 Pages
概要

ベッカー型筋ジストロフィーは、遺伝性の神経変性疾患の一種で、随意筋に症状が現れます。疼痛や走行、跳躍、つま先立ちなどの動作困難、呼吸困難、認識障害などが症状としてあげられます。

当レポートでは、ベッカー型筋ジストロフィーに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ベッカー型筋ジストロフィーの概要

治療薬の開発

  • パイプライン製品:概要

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Milo Biotechnology LLC
  • PTC Therapeutics, Inc.
  • ReveraGen BioPharma, Inc.
  • Sarepta Therapeutics, Inc.
  • Sphaera Pharma Pvt. Ltd

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AAV1-FS-344
  • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD
  • ARM-210
  • ataluren
  • epicatechin
  • Small Molecule for Becker Muscular Dystrophy
  • vamorolone

最新のパイプライン製品情報

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9634IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H2 2017, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 2 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Becker Muscular Dystrophy - Overview
    • Becker Muscular Dystrophy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Becker Muscular Dystrophy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
    • Italfarmaco SpA
    • Milo Biotechnology LLC
    • PTC Therapeutics Inc
    • ReveraGen BioPharma Inc
    • Sarepta Therapeutics Inc
  • Becker Muscular Dystrophy - Drug Profiles
    • AAV1-Follistatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARM-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ataluren - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epicatechin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vamorolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Becker Muscular Dystrophy - Dormant Projects
  • Becker Muscular Dystrophy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference
      • Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference
      • Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound
      • May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound
      • Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Becker Muscular Dystrophy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H2 2017
  • Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2017
  • Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H2 2017
  • Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H2 2017
  • Becker Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Becker Muscular Dystrophy - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Becker Muscular Dystrophy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top